Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $100 to $101.
May 07, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Edwards Lifesciences and raises the price target to $101.
The upgrade in the price target by Barclays, a major financial institution, reflects a positive outlook on Edwards Lifesciences' stock. This endorsement is likely to instill confidence among investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100